Samsung Biologics, a Korean contract development and manufacturing organization (CDMO),  announced its partnership with Kurma Partners, a global biohealthcare venture capital firm, on Tuesday. This collaboration aims to provide support for the development and production of biopharmaceuticals for investee companies.

Kurma Partners, headquartered in Paris, is a venture capital firm with a specialization in investments within the bio-healthcare sector. Established in 2009 as part of Eurazeo, Europe's largest investment group, Kurma Partners operates primarily in the European market. The firm boasts a broad network of connections with 60 major pharmaceutical companies globally and manages a fund totaling 700 million euros.

Samsung Biologics will offer tailored contract development services to biotech companies in which Kurma Partners has made investments.

This agreement underscores Samsung Biologics' commitment to fortify its relationships with potential clients, solidifying its position as a global leader in CDMO business.

Samsung Biologics also intends to expand its capacity to offer comprehensive end-to-end solutions, encompassing services ranging from Contract Development Organization (CDO) and Contract Manufacturing Organization (CMO) to aseptic filling and finishing processes.

"As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies," said John Rim, President and CEO of Samsung Biologics. "With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients."

"We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market." said Daniel Parera, M.D., Partner at Kurma Partners.

Samsung Biologics ventured into the CDO business in 2018 and has successfully secured over 100 contracts within the span of five years.